Evolocumab

¥2,000.00

规格: 1mg

CAS 号:1256937-27-5

英文名字:Evolocumab

质量标准:>95%,蛋白原液
SKU: MB2797-1 分类: , ,

Evolocumab
分子式:C6242H9648N1668O1996S56分子量:141.80KD
简介:Evolocumab is a monoclonal antibody as well as an inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein targeting LDL receptors. Inhibition of PCSK9 could prevent LDL receptors from degradation and promote the removal of LDL-C from blood circulation. Evolocumab is used for the treatment of hyperlipidemia.
产品形式:蛋白原液。每种装于冻存管中,单抗质量为标示数量1MG或者5MG,体积根据其浓度不同略有不同。

质量标准:
Non-reduced CE-SDS:………………………………………….>90%;
SEC-HPLC:………………………………………………………….>95%;
Bacterial Endotoxins Test:…………………………………. .<10EU/ml
Residual Proteins of Host Cell: ……………………………. <100 ng/mg
Exogenous residual DNA: …………………………………. . <100pg/mg
Residual Protein A: ……………………………………………. .<100 ng/mg
Biological Activity:………………………………………….……. .80% to 125% of standard
储存条件:-70 ± 15℃for long-term storage, 2-8℃for short-term storage, away from light.

运输条件:干冰运输
使用建议:
meilunbio提供的产品为蛋白原液形式。每种装于冻存管中,单抗质量为标示数量1MG或者5MG,体积根据其浓度不同略有不同。
使用前可以根据自己实验需求进行稀释,溶剂建议用去离子无菌水(meilunbio货号MA0028,去离子无菌水(细胞培养用水))或者PBS(meilunbio货号MA0015PBS(1X),细胞培养级)。
不建议使用含有防腐成分的稀释液进行稀释,会增加细胞或者动物毒性。
稀释前,计算加入多少体积溶剂,请参考购买批次质检单上蛋白浓度,或者询问我司,
举例,质检单显示该批次单抗蛋白原液蛋白浓度为 50mg/ml
对应5MG包装的蛋白原液体积为5mg(质量)/50mg/ml(浓度)=0.1ML,
实验需求蛋白浓度为10mg/ml, 需要稀释倍数为 50/10=5, 则需要加入0.4ML,即400ul PBS或者无菌去离子水即可。
若给药量为固定质量值,比如单次给药0.5MG,对应蛋白原液给药体积为10ul,建议稀释后,提高给药体积降低误差,因为注射器或者移液器吸头残留会影响实验效果。
稀释后的蛋白溶液,可于2-8度冷藏避光保存不超过2周,不建议长期储存。
避免反复冻融,每次冻融蛋白活性会降低约5%左右。
生物活性(仅来自于公开文献,不保证其有效性)

描述
Evolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9).

靶点

PCSK9,

体内

In mice, a single intravenous injection of evolocumab 10 mg/kg reduced total cholesterol by 20, 26, and 28% at 24, 72, and 144 h after injection, respectively . The magnitude and duration of the effects of evolocumab were dose related: total cholesterol at 3 days after an injection of evolocumab 3, 6, or 10 mg/kg was reduced from baseline by 26, 28, and 36%, respectively. By day 12, total cholesterol levels in all treatment groups were similar to those in control animals.
Reference:Sreeneeranj Kasichayanula, et al. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clin Pharmacokinet. 2018; 57(7): 769–779.

美仑相关产品推荐(更多相关靶点抑制剂请详询官网或客服)

产品编号

品名.

Target

MB2806

aflibercept

VEGFR

MB2786

Alemtuzumab

CD52

MB2787

Alirocumab

PCSK9

MB2789

Avelumab

PDL-1

MB2790

Atezolizumab

PDL-1

MB2791

Bevacizumab

VEGF

MB2792

Cetuximab

EGFR

MB2803

Daratumumab

CD38

MB2794

Denosumab

RANK Ligand

MB2023

Eculizumab

补体蛋白(C5)

MB2795

Etanercept

TNF

MB2784

Adalimumab

TNF-α

MB2773

Infliximab

TNF-α

MB2769

Ipilimumab

CTLA-4

MB2772

Matuzumab

EGFR

MB2766

Mepolizumab

IL-5

MB2767

Nivolumab

PD-1

MB2774

Obinutuzumab

CD20

MB2776

Ofatumumab

CD20

MB2777

Omalizumab

IgE

MB2781

Panitumumab

EGFR

MB2761

Pembrolizumab

PD-1

MB2762

Pertuzumab

HER2

MB2763

Ranibizumab

VEGFR

MB2938

Ramucirumab

VEGFR

MB2749

Rituximab

CD20

MB2757

Secukinumab

IL-17

MB2751

Tocilizumab/Atlizumab

IL-6 receptor

MB2753

Trastuzumab

ErbB2

MB2758

Ustekinumab

IL-12

用途及描述:仅供科研,严禁用于人体(For R&D Only)

我司所售出产品仅供于科研研究用途(非临床科研研究),每次销售产品行为都适用于我司网上所列明的通用销售条款

 

规格

1mg

相关文档

购物车